Tuesday, August 4, 2015

Research Studies

Human Subjects Protection Training
Participate in Research
Researchers
Research Studies 


btqlogo2013.jpg

 

Bitch to Quit Smoking Cessation Research Study

Bitch to Quit (BTQ) is proud to be one of the first studies in the nation focusing on smoking in the LGBTQ community! The study is currently seeking adult lesbian, gay, bisexual, transgender, and queer (LGBTQ) smokers who are interested in quitting smoking. The study includes 6 group-counseling sessions, 8 weeks of nicotine replacement therapy, and compensation for time and travel!

For more information, please
e-mail:
 BTQ@howardbrown.org call 773.388.8868.


Project Adhere

Howard Brown Health Center is the study site for Project Adhere, a research intervention designed to understand the quit smoking and medication adherence needs of HIV+ African American men who have sex with men (MSM). This project is a natural extension of Bitch to Quit, the larger quit smoking research program for the LGBTQ community. Currently, we are seeking African American men for two 90-minute focus groups to assess the quit smoking and medication adherence needs for this community to develop the intervention. Participants will receive $25 for each focus group.

Eligibility criteria include:
1) Identify as African American or Black
2) Identify as a man who has sex with other men
3) be HIV-positive
4) be a smoker
and
5) have a current antiretroviral (HIV medication) prescription.

If you are interested in participating, please contact Kyle Jones in the Research Department at 773.388.1600 ext. 8899 or KyleJ@howardbrown.org.


WebsiteResearchandWalgreens.jpg


Merck, MK1439-018

A Phase 3 Multicenter, Double-Blind, Randomized , Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Doravirine (MK1439) 100mg Once Daily Versus Darunavir 800 mg Once Daily plus Ritonavir 100 mg Once Daily, each in Combination with TRUVADA OR EPZICOM/KIVEXA, in Treatment-Naive HIV-1 Infected Subjects.

For more information, please contact Kenyetta Drummond at KenyettaD@howardbrown.org or 773.572.5116. 


Gilead, GS-US-366-1160

A Phase 3b, Randomized, Double-Blind Study to Evaluate Switching from a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/ Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Subjects.

For more information, please contact Kenyetta Drummond at KenyettaD@howardbrown.org or 773.572.5116. 


 Gilead GS-US-366-1216

A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate  the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects who are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)

For more information, please contact Kenyetta Drummond at KenyettaD@howardbrown.org or 773.572.5116.